CRISPR in Neurodegenerative Diseases Treatment: An Alternative Approach to Current Therapies
Genes · 2025
DOI: 10.3390/genes16080850 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, 2025. Verfasst von Amna Akbar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Bosan Road, Multan 60800, Punjab, Pakistan. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, CRISPR-Cas Systems, Gene Editing, Genetic Therapy. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neurodegenerative diseases (NDs) pose a major challenge to global healthcare systems owing to their devastating effects and limited treatment options. These disorders are characterized by progressive loss of neuronal structure and function, resulting in cognitive and motor impairments. Current therapies primarily focus on symptom management rather than on targeting the underlying causes. However, clustered regularly interspaced short palindromic repeat (CRISPR) technology offers a promising alternative by enabling precise genetic modifications that could halt or even reverse ND progression. CRISPR-Cas9, the most widely used CRISPR system, acts as a molecular scissor targeting specific DNA sequences for editing. By designing guide RNAs (gRNAs) to match sequences in genes associated with NDs, researchers can leverage CRISPR to knockout harmful genes, correct mutations, or insert protective genes. This review explores the potential of CRISPR-based therapies in comparison with traditional treatments for NDs. As research advances, CRISPR has the potential to revolutionize ND treatment by addressing its genetic underpinnings. Ongoing clinical trials and preclinical studies continue to expand our understanding and application of this powerful tool to fight debilitating conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Bosan Road, Multan 60800, Punjab, Pakistan.
- Department of Precision Medicine in Medical, Surgical, and Critical Care (Me.Pre.C.C.), University of Palermo, 90100 Palermo, Italy.
- Institute of Clinical Biochemistry, Clinical Molecular Medicine, and Clinical Laboratory Medicine, Department of Biomedicine, Neurosciences, and Advanced Diagnostics (BIND), University of Palermo, via del Vespro, 129, 9…
- Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi 75270, Sindh, Pakistan.
- Department of Biotechnology, University of Sargodha, University Road, Sargodha 40100, Punjab, Pakistan.
- Department of Laboratory Medicine, University Hospital "P. Giaccone", Via del Vespro, 129, 90127 Palermo, Italy.
ORCID-Profile: Marcello Ciaccio
Zitieren
APA
Akbar, A., Haider, R., Agnello, L., Noor, B., Maqsood, N., Atif, F., Ali, W., Ciaccio, M., & Tariq, H. (2025). CRISPR in Neurodegenerative Diseases Treatment: An Alternative Approach to Current Therapies. Genes. https://doi.org/10.3390/genes16080850
Vancouver
Akbar A, Haider R, Agnello L, Noor B, Maqsood N, Atif F, et al. CRISPR in Neurodegenerative Diseases Treatment: An Alternative Approach to Current Therapies. Genes. 2025. doi:10.3390/genes16080850
BibTeX
@article{Akbar2025,
author = {Akbar, Amna and Haider, Rida and Agnello, Luisa and Noor, Bushra and Maqsood, Nida and Atif, Fatima and Ali, Wajeeha and Ciaccio, Marcello and Tariq, Hira},
title = {CRISPR in Neurodegenerative Diseases Treatment: An Alternative Approach to Current Therapies},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16080850}
}
EUVIMED